Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more
Market Cap & Net Worth: Neuropace Inc (NPCE)
Neuropace Inc (NASDAQ:NPCE) has a market capitalization of $460.31 Million ($460.31 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12751 globally and #5412 in its home market, demonstrating a -1.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuropace Inc's stock price $13.82 by its total outstanding shares 33307734 (33.31 Million).
Neuropace Inc Market Cap History: 2021 to 2026
Neuropace Inc's market capitalization history from 2021 to 2026. Data shows change from $335.74 Million to $460.31 Million (-11.36% CAGR).
Index Memberships
Neuropace Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #346 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1251 of 3165 |
Weight: Neuropace Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neuropace Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuropace Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.66x
Neuropace Inc's market cap is 4.66 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $335.74 Million | $45.18 Million | -$36.08 Million | 7.43x | N/A |
| 2022 | $49.63 Million | $45.52 Million | -$47.08 Million | 1.09x | N/A |
| 2023 | $343.40 Million | $65.42 Million | -$32.96 Million | 5.25x | N/A |
| 2024 | $372.71 Million | $79.91 Million | -$27.14 Million | 4.66x | N/A |
Competitor Companies of NPCE by Market Capitalization
Companies near Neuropace Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Neuropace Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Neuropace Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Neuropace Inc's market cap moved from $335.74 Million to $ 460.31 Million, with a yearly change of -11.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $460.31 Million | -10.49% |
| 2025 | $514.27 Million | +37.98% |
| 2024 | $372.71 Million | +8.54% |
| 2023 | $343.40 Million | +591.95% |
| 2022 | $49.63 Million | -85.22% |
| 2021 | $335.74 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Neuropace Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $460.31 Million USD |
| MoneyControl | $460.31 Million USD |
| MarketWatch | $460.31 Million USD |
| marketcap.company | $460.31 Million USD |
| Reuters | $460.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.